PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma

Melanoma and Skin Cancer

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

Melanoma Res

Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D

doi: 10.1097/CMR.0000000000000744

Melanoma and Skin Cancer

GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma

Br J Dermatol.

Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, Hassel JC, Herbst R, Utikal JS, Weide B, Gutzmer R, Meier F, Koelsche C, Hadaschik E, Sucker A, Reis H, Merkelbach-Bruse S, Siewert M, Sahm F, von Deimling A, Cosgarea I, Zimmer L, Schadendorf D, Schilling B, Griewank KG

doi: 10.1111/bjd.18947.

Melanoma and Skin CancerFurther Publications Dermatology

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

N Engl J Med

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S, IMCgp100-202 Investigators.

doi: 10.1056/NEJMoa2103485

Melanoma and Skin Cancer

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

J Natl Cancer Inst.

Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S

doi: 10.1093/jnci/djx198.

Melanoma and Skin Cancer

Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods

Onco Targets Ther.

Duan H, Jiang K, Wei D, Zhang L, Cheng D, Lv M, Xu Y, He A

doi: 10.2147/OTT.S146663.

Melanoma and Skin Cancer

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

Semin Oncol

Pala L, Conforti F, Saponara M, De Pas T, Giugliano F, Omodeo Salè E, Jemos C, Marco R, Andrea A, Quaglino P, Fava P, Fierro MT, Queirolo P

doi: 10.1053/j.seminoncol.2020.07.010

RECOMMENDED

Immunotherapy

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

doi: smw.2019.14697.

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

Melanoma and Skin Cancer

Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression

Melanoma Res

Mondal SK, Whiteside TL

doi: 10.1097/CMR.0000000000000762

Related content

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma

Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression